(Reuters) – The National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine from a trial testing Gilead Sciences Inc’s remdesivir showed the drug was superior to the standard of care for COVID-19.
Last month, the NIH announced early data from the study, which began in February with 1,063 participants in 10 countries.(https://bit.ly/2Tvd6I1)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni)
